OPKO Health, Inc. (OPK) Key Metrics

NASDAQ: OPKValuation, returns, debt and efficiency ratios over 10 years.

OPK valuation today

Trailing 12 months · as of October 18, 2026
Market cap
$1.14B
Enterprise value
$1.37B
P/E (TTM)
—
Forward P/E
53.8
PEG ratio
93.65
Price / sales
1.9
10-yr median 1.6
Price / book
1.1
10-yr median 0.9
EV / EBITDA
24.9
10-yr median 28.2
Dividend yield
—
Beta
1.50

OPK key metrics, 2016–2025

Fiscal year ended December 31, 2025 · U.S. dollars

OPK valuation Price multiples at each fiscal year-end price.

Price / sales+9.0%
1.6
2025 · hover or tap a bar for each year
2016: 3.8 (−62.6%)2017: 2.8 (−25.8%)2018: 1.7 (−39.3%)2019: 1.0 (−43.7%)2020: 1.8 (+81.7%)2021: 1.8 (−0.4%)2022: 0.9 (−49.0%)2023: 1.3 (+46.9%)2024: 1.4 (+8.8%)2025: 1.6 (+9.0%)
20162025
Price / book−0.1%
0.7
2025 · hover or tap a bar for each year
2016: 2.2 (−12.1%)2017: 1.5 (−33.4%)2018: 1.0 (−35.9%)2019: 0.5 (−43.1%)2020: 1.5 (+179.3%)2021: 1.8 (+22.2%)2022: 0.6 (−68.9%)2023: 0.8 (+42.0%)2024: 0.7 (−8.6%)2025: 0.7 (−0.1%)
20162025
Free cash flow yield+0.3 pts
−20.2%
2025 · hover or tap a bar for each year
2016: 0.2% (−2.8 pts)2017: −5.1% (−5.2 pts)2018: −8.0% (−3.0 pts)2019: −21.2% (−13.1 pts)2020: 0.2% (+21.4 pts)2021: 0.2% (0.0 pts)2022: −13.3% (−13.5 pts)2023: −3.9% (+9.4 pts)2024: −20.4% (−16.5 pts)2025: −20.2% (+0.3 pts)
20162025

OPK valuation history

Fiscal year-endToday10-year median

OPK returns on capital

ROEROICROA

Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.

OPK debt vs cash

Total debtCash & short-term investments

Debt includes short- and long-term borrowings and, where reported, lease liabilities.

OPK cash returned to shareholders

DividendsBuybacksFree cash flow

OPK price vs earnings per share

Share price at year-endEPS (right axis)

OPK key metrics

2016–2025
OPKO Health, Inc. key metrics by fiscal year
2025202420232022202120202019201820172016
Valuation
Market capitalization$946.4M$1.02B$1.14B$898.8M$3.12B$2.53B$875.3M$1.71B$2.74B$4.67B
Enterprise value$1.01B$1.09B$1.37B$1.05B$3.24B$2.75B$1.08B$1.82B$2.81B$4.59B
P/E ratio—————82.7————
Price / sales1.61.41.30.91.81.81.01.72.83.8
Price / book0.70.70.80.61.81.50.51.01.52.2
Price / free cash flow————504.3436.8———549.3
Price / operating cash flow————81.364.1———145.7
EV / sales1.71.51.61.01.81.91.21.82.93.8
EV / EBITDA—8.1——38.717.6———638.7
EV / free cash flow————523.8475.1———539.9
Earnings yield−23.8%−5.2%−16.6%−36.5%−1.0%1.2%−36.0%−9.0%−11.1%−1.0%
Free cash flow yield−20.2%−20.4%−3.9%−13.3%0.2%0.2%−21.2%−8.0%−5.1%0.2%
Dividend yield——————0.0%—0.0%0.0%
Shareholder yield (dividends + buybacks)5.0%8.8%0.0%0.0%——0.0%0.0%0.0%0.0%
Share price at fiscal year-end$1.26$1.47$1.51$1.25$4.81$3.95$1.47$3.01$4.90$9.30
Per share
Revenue per share$0.81$1.03$1.15$1.40$2.74$2.24$1.51$1.75$1.73$2.43
Earnings per share−$0.30−$0.08−$0.25−$0.46−$0.05$0.05−$0.53−$0.27−$0.55−$0.10
Operating cash flow per share−$0.24−$0.26−$0.04−$0.13$0.06$0.06−$0.29−$0.19−$0.16$0.06
Free cash flow per share−$0.25−$0.30−$0.06−$0.17$0.01$0.01−$0.31−$0.24−$0.25$0.02
Cash per share$0.49$0.62$0.13$0.21$0.21$0.11$0.14$0.17$0.16$0.34
Book value per share$1.69$1.97$1.85$2.17$2.60$2.61$2.71$3.16$3.30$4.17
Tangible book value per share$0.36$0.04−$0.19−$0.07$0.39−$0.12−$0.54−$0.43−$0.37$0.08
Dividends per share——————$0.00—$0.00$0.00
Capex per share$0.02$0.04$0.02$0.03$0.05$0.05$0.02$0.05$0.08$0.05
Debt per share$0.58$0.73$0.43$0.42$0.39$0.46$0.48$0.38$0.28$0.18
Shares outstanding751.1M694.0M751.8M719.1M648.1M640.7M595.5M566.7M559.2M502.0M
Change in shares outstanding+8.2%−7.7%+4.5%+11.0%+1.2%+7.6%+5.1%+1.3%+11.4%+0.4%
Returns & profitability
Return on equity (ROE)−17.1%−3.9%−12.8%−20.2%−1.8%1.9%−18.5%−8.4%−15.5%−2.4%
Return on invested capital (ROIC)−12.5%−7.9%−7.4%−10.2%0.8%2.0%−11.6%−7.1%−11.1%−3.0%
Return on assets (ROA)−10.9%−2.5%−9.0%−14.4%−1.2%1.3%−13.2%−6.1%−11.4%−1.7%
Return on tangible assets−24.2%−6.2%−39.5%−59.4%−3.1%4.2%−83.9%−36.9%−56.4%−6.8%
Free cash flow margin−31.4%−29.2%−5.2%−11.9%0.3%0.4%−20.5%−13.8%−14.3%0.7%
Income quality (OCF / net income)—————1.29————
Financial health
Total debt$433.6M$504.4M$326.6M$305.5M$254.8M$294.6M$288.3M$213.5M$158.0M$88.7M
Cash & short-term investments$369.1M$431.9M$95.9M$153.2M$134.7M$72.2M$85.5M$96.5M$91.5M$168.7M
Net debt$64.5M$72.5M$230.7M$152.4M$120.0M$222.4M$202.8M$117.0M$66.5M−$80.0M
Debt / equity0.340.370.240.200.150.180.180.120.090.04
Debt / assets0.220.230.160.140.110.120.120.090.060.03
Net debt / EBITDA—0.54——1.441.43———−11.13
Current ratio3.973.431.551.852.491.391.301.241.121.84
Quick ratio3.523.131.221.502.231.041.091.070.961.66
Interest coverage-2.0-3.2-11.6-18.81.02.6-12.7-14.4-41.9-9.9
Working capital$435.2M$469.0M$109.4M$181.0M$493.0M$147.7M$74.9M$60.9M$36.8M$220.3M
Invested capital$1.33B$1.44B$1.62B$1.71B$1.81B$1.89B$1.82B$1.91B$1.91B$2.01B
Tangible asset value$267.4M$24.6M−$144.3M−$52.7M$252.6M−$74.3M−$319.2M−$244.7M−$204.7M$37.9M
Net current asset value−$82.1M−$172.7M−$313.0M−$211.1M$108.4M−$278.3M−$370.5M−$342.1M−$397.5M−$191.2M
Graham number—————$1.67————
Graham net-net per share−$0.22−$0.38−$0.53−$0.42−$0.52−$0.68−$0.78−$0.74−$0.88−$0.59
Capital allocation
Dividends paid——————$3,000—$0$0
Share buybacks (net)$47.0M$90.2M$272,000$0——$3,000$0$0$0
Dividends + buybacks / free cash flow—————————0.0%
Capex / revenue2.0%3.5%1.9%2.4%1.8%2.3%1.4%2.8%4.8%1.9%
Capex / operating cash flow————83.9%85.3%———73.5%
Capex / depreciation0.130.250.150.230.410.390.140.290.460.24
Stock-based compensation / revenue1.8%1.5%1.3%1.8%0.8%0.6%1.5%2.2%2.9%3.5%
R&D / revenue20.4%14.8%10.4%7.4%4.3%5.2%13.1%13.7%13.1%9.3%
SG&A / revenue36.7%42.7%34.9%37.1%26.4%24.8%38.1%36.2%53.9%40.2%
Efficiency
Days sales outstanding83.672.258.975.358.458.564.764.382.568.5
Days of inventory on hand46.755.646.840.933.537.930.527.728.425.9
Days payables outstanding33.653.045.738.028.033.335.036.737.637.6
Cash conversion cycle (days)96.874.860.078.263.963.060.255.273.356.8
Receivables turnover4.365.056.194.856.256.245.645.674.435.33
Payables turnover10.866.897.989.6113.0510.9510.429.949.719.71
Inventory turnover7.816.577.808.9210.909.6311.9613.2012.8414.07
Asset turnover0.290.340.410.440.730.600.380.390.360.44
Average receivables$139.1M$141.1M$139.4M$207.1M$283.9M$230.0M$159.8M$174.5M$218.3M$229.2M
Average payables$44.1M$58.4M$68.3M$74.5M$91.5M$81.7M$55.0M$60.9M$63.8M$62.9M
Average inventory$61.3M$61.2M$69.9M$80.3M$109.4M$92.9M$47.9M$45.8M$48.3M$43.5M
Intangibles / total assets51.8%60.9%76.2%74.5%59.7%70.6%83.8%83.1%79.1%74.2%

Computed from OPK's annual financial statements (latest annual report filed February 26, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.

OPK valuation and financial ratios

OPKO Health earned a return on equity of −17.1% and a return on invested capital of −12.5% in fiscal 2025. It ended the year with $433.6 million of debt and $369.1 million in cash and short-term investments, net debt of $64.5 million. It returned $47.0 million to shareholders: $0 in dividends and $47.0 million in share buybacks. The share count rose 49.6% from 502.0M to 751.1M over 9 years.

See the OPK income statement, the OPK chart for price history, or the OPK stock overview for the latest quote and news.

OPK key metrics FAQ

What is OPKO Health's return on equity?

OPKO Health's return on equity (ROE) was −17.1% in fiscal 2025: net income of -$225.7 million on average shareholders' equity of $1.3 billion.

What is OPKO Health's ROIC?

OPKO Health's return on invested capital was −12.5% in fiscal 2025, using after-tax operating income divided by average debt plus equity minus cash.

How much debt does OPKO Health have?

OPKO Health had total debt of $433.6 million at the end of fiscal 2025, a debt-to-equity ratio of 0.34.

Does OPKO Health buy back its shares?

Yes. OPKO Health spent $47.0 million on net share repurchases in fiscal 2025 Shares outstanding changed +8.2% over the year, to 751.1M..

What is OPKO Health's free cash flow yield?

OPKO Health generated -$190.8 million of free cash flow in fiscal 2025, a free cash flow yield of −20.2% on its market value at year-end ($946.4 million).

What is OPKO Health's current ratio?

OPKO Health's current ratio was 3.97 at the end of fiscal 2025: current assets were 3.97 times current liabilities.

Diagnostics & Research key metrics